HUMAN PROGUANYLIN ELISA

Product Data Sheet

Cat. No.: RD191046100R

For Research Use Only
## CONTENTS

1. INTENDED USE 3
2. STORAGE, EXPIRATION 3
3. INTRODUCTION 4
4. TEST PRINCIPLE 4
5. PRECAUTIONS 5
6. TECHNICAL HINTS 5
7. REAGENT SUPPLIED 6
8. MATERIAL REQUIRED BUT NOT SUPPLIED 6
9. PREPARATION OF REAGENTS 7
10. PREPARATION OF SAMPLES 8
11. ASSAY PROCEDURE 9
12. CALCULATIONS 10
13. PERFORMANCE CHARACTERISTICS 11
14. DEFINITION OF THE STANDARD 15
15. PRELIMINARY POPULATION AND CLINICAL DATA 15
16. METHOD COMPARISON 17
17. TROUBLESHOOTING AND FAQS 17
18. REFERENCES 18
19. EXPLANATION OF SYMBOLS 19

This kit is manufactured by:
BioVendor – Laboratorní medicína, a.s.

Use only the current version of Product Data Sheet enclosed with the kit!
1. INTENDED USE

The RD191046100R Human Proguanylin ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human proguanylin.

Features

- **It is intended for research use only**
- The total assay time is less than 3 hours
- The kit measures total proguanylin in serum, plasma
- Assay format is 96 wells
- Standard is recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized

2. STORAGE, EXPIRATION

Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

For stability of opened reagents see Chapter 9.
3. INTRODUCTION

Proguanylin, the 116-amino acid prohormone, is a bioactive form of human guanylin that acts on intestinal guanylate cyclase, thereby regulating intestinal fluid and electrolyte transport through the second messenger, cyclic GMP (cGMP). The cGMP increase inhibits salt absorption and stimulates chloride secretion into the gut. This imbalance of ions is accompanied by a massive accumulation of water in the gut that gives rise to diarrhea and dehydration characteristic of enterotoxin activity.

Proguanylin is found in circulation and plays an endocrine role by regulating the function of tissues such as the kidney and liver. Proguanylin is a significant marker in renal insufficiency. Plasma levels of proguanylin increase in patients with chronic renal failure who were undergoing hemodialysis.

Studies have shown, that serum levels of proguanylin has rise in patients with Cohn syndrome therefore it could be used as a novel marker in diagnostic and therapy of cardiac failure.

Areas of investigation:
Renal disease
Heart failure

4. TEST PRINCIPLE

In the BioVendor Human Proguanylin ELISA, standards and samples are incubated in microplate wells pre-coated with polyclonal anti-human proguanylin antibody. After 60 minutes incubation and washing, polyclonal anti-human proguanylin antibody, conjugated with horseradish peroxidase (HRP) is added to the wells and incubated for 60 minutes with captured proguanylin. Following another washing step, the remaining HRP conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured spectrophotometrically at 450 nm. The absorbance is proportional to the concentration of proguanylin. A standard curve is constructed by plotting absorbance values against concentrations of standards, and concentrations of unknown samples are determined using this standard curve.
5. PRECAUTIONS

- For professional use only
- Wear gloves and laboratory coats when handling immunodiagnostic materials
- Do not drink, eat or smoke in the areas where immunodiagnostic materials are being handled
- This kit may contain components of human or animal origin. These materials should be handled as potentially infectious.
- Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide and tetramethylbenzidine (TMB). Wear gloves and eye and clothing protection when handling these reagents. Stop and/or Substrate Solutions may cause skin/eyes irritation. In case of contact with the Stop Solution and the Substrate Solution wash skin/eyes thoroughly with water and seek medical attention, when necessary
- The materials must not be pipetted by mouth

6. TECHNICAL HINTS

- Reagents with different lot numbers should not be mixed
- Use thoroughly clean glassware
- Use deionized (distilled) water, stored in clean containers
- Avoid any contamination among samples and reagents. For this purpose, disposable tips should be used for each sample and reagent
- Substrate Solution should remain colourless until added to the plate. Keep Substrate Solution protected from light
- Stop Solution should remain colourless until added to the plate. The colour developed in the wells will turn from blue to yellow immediately after the addition of the Stop Solution. Wells that are green in colour indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution
- Dispose of consumable materials and unused contents in accordance with applicable national regulatory requirements
7. REAGENT SUPPLIED

<table>
<thead>
<tr>
<th>Kit Components</th>
<th>State</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody Coated Microtiter Strips</td>
<td>ready to use</td>
<td>96 wells</td>
</tr>
<tr>
<td>Conjugate Solution</td>
<td>ready to use</td>
<td>13 ml</td>
</tr>
<tr>
<td>Master Standard</td>
<td>lyophilized</td>
<td>2 vials</td>
</tr>
<tr>
<td>Dilution Buffer</td>
<td>ready to use</td>
<td>20 ml</td>
</tr>
<tr>
<td>Wash Solution Concentrate (10x)</td>
<td>concentrated</td>
<td>100 ml</td>
</tr>
<tr>
<td>Substrate Solution</td>
<td>ready to use</td>
<td>13 ml</td>
</tr>
<tr>
<td>Stop Solution</td>
<td>ready to use</td>
<td>13 ml</td>
</tr>
<tr>
<td>Product Data Sheet + Certificate of Analysis</td>
<td>-</td>
<td>1 pc</td>
</tr>
</tbody>
</table>

8. MATERIAL REQUIRED BUT NOT SUPPLIED

- Deionized (distilled) water
- Test tubes for diluting samples
- Glassware (graduated cylinder and bottle) for Wash Solution (Dilution Buffer)
- Precision pipettes to deliver 10-1000 \( \mu l \) with disposable tips
- Multichannel pipette to deliver 100 \( \mu l \) with disposable tips
- Absorbent material (e.g. paper towels) for blotting the microtitrate plate after washing
- Vortex mixer
- Orbital microplate shaker capable of approximately 300 rpm
- Microplate washer (optional). [Manual washing is possible but not preferable.]
- Microplate reader with 450 \( \pm \) 10 nm filter, preferably with reference wavelength 630 nm (alternatively another one from the interval 550-650 nm)
- Software package facilitating data generation and analysis (optional)
9. PREPARATION OF REAGENTS

- All reagents need to be brought to room temperature prior to use.
- Always prepare only the appropriate quantity of reagents for your test.
- Do not use components after the expiration date marked on their label.

- Assay reagents supplied ready to use:

  **Antibody Coated Microtiter Strips**
  **Stability and storage:**
  Return the unused strips to the provided aluminium zip-sealed bag with desicant and seal carefully. Remaining Microtiter Strips are stable 3 months stored at 2-8°C and protected from the moisture.

  **Conjugate Solution**
  **Dilution Buffer**
  **Substrate Solution**
  **Stop Solution**
  **Stability and storage:**
  Opened reagents are stable 3 months when stored at 2-8°C.

- Assay reagents supplied concentrated or lyophilized:

  **Human Proguanylin Master Standard**
  **Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution of standard!!!**
  Reconstitute the lyophilized Master Standard with Dilution Buffer just prior to the assay. Let it dissolve at least 15 minutes with occasionally gently shaking (not to foam). The resulting concentration of the human proguanylin in the stock solution is **10 ng/ml**.

  Prepare set of standards using Dilution Buffer as follows:

<table>
<thead>
<tr>
<th>Volume of Standard</th>
<th>Dilution Buffer</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock</td>
<td>-</td>
<td>10 ng/ml</td>
</tr>
<tr>
<td>250 µl of stock</td>
<td>250 µl</td>
<td>5 ng/ml</td>
</tr>
<tr>
<td>250 µl of 5 ng/ml</td>
<td>250 µl</td>
<td>2.5 ng/ml</td>
</tr>
<tr>
<td>250 µl of 2.5 ng/ml</td>
<td>250 µl</td>
<td>1.25 ng/ml</td>
</tr>
<tr>
<td>250 µl of 1.25 ng/ml</td>
<td>250 µl</td>
<td>0.63 ng/ml</td>
</tr>
<tr>
<td>250 µl of 0.63 ng/ml</td>
<td>250 µl</td>
<td>0.31 ng/ml</td>
</tr>
</tbody>
</table>

**Prepared Standards are ready to use, do not dilute them.**
**Stability and storage:**
The reconstituted Master Standard must be used immediately or stored frozen at -20 °C for 3 months. Avoid repeating freezing/thawing cycles. **Do not store the diluted Standard solutions.**

**Wash Solution**
Dilute Wash Solution Concentrate (10x) ten-fold in distilled water to prepare a 1x working solution, e.g. 100 ml of Wash Solution Concentrate (10x)+ 900 ml of distilled water for use of all 96-wells.

**Stability and storage:**
The diluted Wash Solution is stable 1 month when stored at 2-8°C. Opened Wash Solution Concentrate (10x) is stable 3 months when stored at 2-8°C.

10. **PREPARATION OF SAMPLES**

The kit measures human proguanylin in serum, plasma.

Samples should be assayed immediately after collection or should be stored at -20°C. Mix thawed samples thoroughly just prior to the assay and avoid repeated freeze/thaw cycles, which may cause erroneous results. Avoid using hemolyzed or lipemic samples.

Dilute samples 5x with the Dilution Buffer just prior to the assay (e.g. 30 µl of sample + 120 µl of Dilution Buffer when assaying samples as singlets or preferably 50 µl of sample + 200 µl of Dilution Buffer for duplicates. **Mix well** (not to foam). Vortex is recommended.

**Stability and storage:**
Samples should be stored at -20°, or preferably at -70°C for long-term storage. Avoid repeated freeze/thaw cycles. **Do not store the diluted samples.**

See Chapter 13 for effect of sample matrix (serum/plasma) on the concentration of human proguanylin.

*Note:* It is recommended to use a precision pipette and a careful technique to perform the dilution in order to get precise results.
11. ASSAY PROCEDURE

1. Pipet 100 µl of standards, Dilution Buffer (=Blank) and samples, preferably in duplicates, into the appropriate wells. See Figure 1 for example of work sheet.

2. Incubate the plate at room temperature (ca. 25°C) for 1 hour, shaking at ca. 300 rpm on an orbital microplate shaker.

3. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.

4. Add 100 µl of Conjugate Solution into each well.

5. Incubate the plate at room temperature (ca. 25°C) for 1 hour, shaking at ca. 300 rpm on an orbital microplate shaker.

6. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.

7. Add 100 µl of Substrate Solution into each well. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminium foil is recommended.

8. Incubate the plate for 10 minutes at room temperature. The incubation time may be extended [up to 20 minutes] if the reaction temperature is below than 20°C. Do not shake the plate during the incubation.

9. Stop the colour development by adding 100 µl of Stop Solution.

10. Determine the absorbance of each well using a microplate reader set to 450 nm, preferably with the reference wavelength set to 630 nm (acceptable range: 550 - 650 nm). Subtract readings at 630 nm (550 - 650 nm) from the readings at 450 nm. The absorbance should be read within 5 minutes following step 9.

Note 1: If some samples and standard/s have absorbances above the upper limit of your microplate reader, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine proguanylin concentration of off-scale standards and samples. The readings at 405 nm should not replace the readings for samples that were “in range” at 450 nm.

Note 2: Manual washing: Aspirate wells and pipet 0.35 ml Wash Solution into each well. Aspirate wells and repeat twice. After final wash, invert and tap the plate strongly against paper towel. Make certain that Wash Solution has been removed entirely.
Figure 1: Example of a work sheet.

12. CALCULATIONS

Most microplate readers perform automatic calculations of analyte concentration. The standard curve is constructed by plotting the mean absorbance (Y) of Standards against the known concentration (X) of Standards in logarithmic scale, using the four-parameter algorithm. Results are reported as concentration of proguanylin (ng/ml) in samples.

Alternatively, the logit log function can be used to linearize the standard curve, i.e. logit of the mean absorbance (Y) is plotted against log of the known concentration (X) of Standards

The measured concentration of samples calculated from the standard curve must be multiplied by their respective dilution factor, because they have been diluted prior to the assay, e.g. 1.3 ng/ml (from standard curve) x 5 (dilution factor) = 6.5 ng/ml.
Figure 2: Typical Standard Curve for Human Proguanylin ELISA.

13. PERFORMANCE CHARACTERISTICS

Typical analytical data of BioVendor Human Proguanylin ELISA are presented in this chapter

- **Sensitivity**
  Limit of Detection (LOD) (defined as concentration of analyte giving absorbance higher than mean absorbance of blank* plus three standard deviations of the absorbance of blank: $A_{\text{blank}} + 3\times SD_{\text{blank}}$) is calculated from the real human proguanylin values in wells and is 0.06 ng/ml.
  *Dilution Buffer is pipetted into blank wells.

- **Limit of assay**
  Samples with absorbances exceeding the absorbance of the highest standard should be measured again with higher dilution. The final concentration of samples calculated from the standard curve must be multiplied by the respective dilution factor.
• **Specificity**
The antibodies used in this ELISA are specific for human proguanylin with no detectable crossreactivities to human prouroguanylin and human uroguanylin.

Sera of several mammalian species were measured in the assay. See results below. For details please contact us at info@biovendor.com.

<table>
<thead>
<tr>
<th>Mammalian serum sample</th>
<th>Observed crossreactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bovine</td>
<td>no</td>
</tr>
<tr>
<td>Cat</td>
<td>no</td>
</tr>
<tr>
<td>Dog</td>
<td>no</td>
</tr>
<tr>
<td>Goat</td>
<td>no</td>
</tr>
<tr>
<td>Hamster</td>
<td>no</td>
</tr>
<tr>
<td>Horse</td>
<td>no</td>
</tr>
<tr>
<td>Monkey</td>
<td>no</td>
</tr>
<tr>
<td>Mouse</td>
<td>no</td>
</tr>
<tr>
<td>Pig</td>
<td>no</td>
</tr>
<tr>
<td>Rabbit</td>
<td>no</td>
</tr>
<tr>
<td>Rat</td>
<td>no</td>
</tr>
<tr>
<td>Sheep</td>
<td>no</td>
</tr>
</tbody>
</table>

**Presented results are multiplied by respective dilution factor**

• **Precision**

  **Intra-assay (Within-Run) (n=8)**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean (ng/ml)</th>
<th>SD (ng/ml)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9.01</td>
<td>0.05</td>
<td>5.78</td>
</tr>
<tr>
<td>2</td>
<td>11.61</td>
<td>0.05</td>
<td>4.59</td>
</tr>
</tbody>
</table>

  **Inter assay (Run-to-Run) (n=6)**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean (ng/ml)</th>
<th>SD (ng/ml)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>53.08</td>
<td>0.26</td>
<td>4.89</td>
</tr>
<tr>
<td>2</td>
<td>9.02</td>
<td>0.03</td>
<td>3.39</td>
</tr>
</tbody>
</table>
• **Spiking Recovery**
  Serum samples were spiked with different amounts of human proguanylin and assayed.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Observed (ng/ml)</th>
<th>Expected (ng/ml)</th>
<th>Recovery O/E (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>22.7</td>
<td>21.4</td>
<td>106.1</td>
</tr>
<tr>
<td></td>
<td>32.7</td>
<td>33.9</td>
<td>96.5</td>
</tr>
<tr>
<td></td>
<td>50.6</td>
<td>58.9</td>
<td>85.9</td>
</tr>
<tr>
<td>2</td>
<td>12.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>22.6</td>
<td>25.4</td>
<td>89.0</td>
</tr>
<tr>
<td></td>
<td>35.4</td>
<td>37.9</td>
<td>93.4</td>
</tr>
<tr>
<td></td>
<td>63.1</td>
<td>62.9</td>
<td>100.3</td>
</tr>
</tbody>
</table>

• **Linearity**
  Serum samples were serially diluted with Dilution Buffer and assayed.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Dilution</th>
<th>Observed (ng/ml)</th>
<th>Expected (ng/ml)</th>
<th>Recovery O/E (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-</td>
<td>49.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2x</td>
<td>24.3</td>
<td>24.8</td>
<td>98.0</td>
</tr>
<tr>
<td></td>
<td>4x</td>
<td>12.8</td>
<td>12.4</td>
<td>103.2</td>
</tr>
<tr>
<td></td>
<td>8x</td>
<td>6.1</td>
<td>6.2</td>
<td>98.4</td>
</tr>
<tr>
<td>2</td>
<td>-</td>
<td>48.3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2x</td>
<td>22.7</td>
<td>24.2</td>
<td>94.0</td>
</tr>
<tr>
<td></td>
<td>4x</td>
<td>11.6</td>
<td>12.1</td>
<td>96.1</td>
</tr>
<tr>
<td></td>
<td>8x</td>
<td>5.6</td>
<td>6.0</td>
<td>92.8</td>
</tr>
</tbody>
</table>
• **Effect of Sample Matrix**

EDTA, citrate and heparin plasmas were compared to respective serum samples from the same 10 individuals. However, we observed low correlation among serum and plasma proguanylin values. Results are shown below:

<table>
<thead>
<tr>
<th>Volunteer No.</th>
<th>Serum (ng/ml)</th>
<th>Plasma (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EDTA</td>
</tr>
<tr>
<td>1</td>
<td>8.7</td>
<td>5.9</td>
</tr>
<tr>
<td>2</td>
<td>7.3</td>
<td>17.8</td>
</tr>
<tr>
<td>3</td>
<td>15.4</td>
<td>19.3</td>
</tr>
<tr>
<td>4</td>
<td>6.5</td>
<td>8.0</td>
</tr>
<tr>
<td>5</td>
<td>13.3</td>
<td>10.5</td>
</tr>
<tr>
<td>6</td>
<td>10.9</td>
<td>11.5</td>
</tr>
<tr>
<td>7</td>
<td>11.2</td>
<td>10.3</td>
</tr>
<tr>
<td>8</td>
<td>8.8</td>
<td>10.3</td>
</tr>
<tr>
<td>9</td>
<td>4.3</td>
<td>11.5</td>
</tr>
<tr>
<td>10</td>
<td>21.0</td>
<td>13.8</td>
</tr>
</tbody>
</table>

Mean (ng/ml)

- 10.7
- 11.9
- 10.8
- 14.5

Mean Plasma/Serum (%)

- 111
- 100
- 135

---

**Fig. 3:** Proguanylin levels measured using Human Proguanylin ELISA from 10 individuals using serum, EDTA, citrate and heparin plasma, respectively.
- **Diurnal Variation**
  Diurnal variation of proguanylin levels in serum was determined in 4 patients in course of 24 hours.

![Diurnal Variation of Serum Proguanylin Levels](image)

14. **DEFINITION OF THE STANDARD**

The Standard used in this kit is recombinant protein. The recombinant human proguanylin, produced in *E.coli*, is 11.5 kDa protein containing 104 amino acid residues.

15. **PRELIMINARY POPULATION AND CLINICAL DATA**

The following results were obtained when serum from 234 unselected donors (142 women + 92 men), 5-85 years old were assayed with the Biovendor Human Proguanylin ELISA kit in our laboratory.

The presented data should be regarded only as guideline.
<table>
<thead>
<tr>
<th>Sex</th>
<th>Age (years)</th>
<th>n</th>
<th>Mean (ng/ml)</th>
<th>Median (ng/ml)</th>
<th>SD</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>5-18</td>
<td>10</td>
<td>10.6</td>
<td>9.6</td>
<td>2.6</td>
<td>6.5</td>
<td>16.3</td>
</tr>
<tr>
<td></td>
<td>23-49</td>
<td>34</td>
<td>11.5</td>
<td>11.3</td>
<td>3.7</td>
<td>3.6</td>
<td>22.6</td>
</tr>
<tr>
<td></td>
<td>50-85</td>
<td>48</td>
<td>11.9</td>
<td>10.9</td>
<td>4.6</td>
<td>4.2</td>
<td>22.7</td>
</tr>
<tr>
<td>Women</td>
<td>4-17</td>
<td>7</td>
<td>7.7</td>
<td>7.2</td>
<td>5.7</td>
<td>1.4</td>
<td>19.1</td>
</tr>
<tr>
<td></td>
<td>20-48</td>
<td>58</td>
<td>11.1</td>
<td>10.2</td>
<td>3.5</td>
<td>4.9</td>
<td>23.0</td>
</tr>
<tr>
<td></td>
<td>50-85</td>
<td>48</td>
<td>11.9</td>
<td>10.9</td>
<td>4.6</td>
<td>4.2</td>
<td>22.7</td>
</tr>
</tbody>
</table>

Figure 5: Human proguanylin concentration plotted against donor age and sex.

- Reference range
The data quoted in these instructions should be used for guidance only. It is recommended that each laboratory include its own panel of control samples in the assay. Each laboratory should establish its own normal and pathological reference ranges for human proguanylin levels with the assay.
16. METHOD COMPARISON

The BioVendor Human Proguanylin ELISA has not been compared to any commercial immunoassay.

17. TROUBLESHOOTING AND FAQS

Weak signal in all wells
Possible explanations:
- Omission of a reagent or a step
- Improper preparation or storage of a reagent
- Assay performed before reagents were allowed to come to room temperature
- Manual washing
- Improper wavelength when reading absorbance

High signal and background in all wells
Possible explanations:
- Improper or inadequate washing
- Overdeveloping; incubation time with Substrate Solution should be decreased before addition of Stop Solution
- Incubation temperature over 30°C

High coefficient of variation (CV)
Possible explanation:
- Improper or inadequate washing
- Improper mixing Standards or samples
18. REFERENCES

**References to proguanylin:**


**References to this product:**


**For more references on this product see our WebPages at www.biovendor.com**
### 19. EXPLANATION OF SYMBOLS

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>REF</td>
<td>Catalogue number</td>
</tr>
<tr>
<td>Cont.</td>
<td>Content</td>
</tr>
<tr>
<td>LOT</td>
<td>Lot number</td>
</tr>
<tr>
<td>⚠️</td>
<td>Attention, see instructions for use</td>
</tr>
<tr>
<td>🦠</td>
<td>Potential biological hazard</td>
</tr>
<tr>
<td>⌛️</td>
<td>Expiry date</td>
</tr>
<tr>
<td>🔄 2 °C</td>
<td>Storage conditions</td>
</tr>
<tr>
<td>🔨</td>
<td>Name and registered office of the manufacturer</td>
</tr>
</tbody>
</table>
Assay Procedure Summary

Antibody Coated Microtiter Strips

- Reconstitute Master Standard, prepare set of standards

Add standards and samples
100 μl

- Dilute samples 5x

 Prepare Wash Solution

Wash 3x

Add Conjugate Solution
100 μl

- Incubate at RT for 1 hour / 300 rpm

Wash 3x

Add Substrate Solution
100 μl

- Incubate at RT for 10 min

Add Stop Solution
100 μl

Read absorbance and calculate results